353 related articles for article (PubMed ID: 15121040)
21. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
Konnopka A; Conrad K; Baerwald C; König HH
Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
[TBL] [Abstract][Full Text] [Related]
23. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
Boonen A; van der Heijde D; Severens JL; Boendermaker A; Landewé R; Braun J; Brandt J; Sieper J; van der Linden S
Ann Rheum Dis; 2006 Feb; 65(2):201-8. PubMed ID: 16014677
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
Bansback NJ; Brennan A; Ghatnekar O
Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
[TBL] [Abstract][Full Text] [Related]
25. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G
Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150
[TBL] [Abstract][Full Text] [Related]
26. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
[TBL] [Abstract][Full Text] [Related]
27. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
Kobelt G; Eberhardt K; Geborek P
Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy.
Walan A; Wahlqvist P
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S79-88. PubMed ID: 10379474
[TBL] [Abstract][Full Text] [Related]
29. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care.
Fendrick AM
Am J Manag Care; 2002 Nov; 8(17 Suppl):S529-41. PubMed ID: 12458822
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
31. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
[TBL] [Abstract][Full Text] [Related]
33. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
[TBL] [Abstract][Full Text] [Related]
34. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.
Brennan A; Bansback N; Reynolds A; Conway P
Rheumatology (Oxford); 2004 Jan; 43(1):62-72. PubMed ID: 12890861
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
Merkesdal S; Kirchhoff T; Wolka D; Ladinek G; Kielhorn A; Rubbert-Roth A
Eur J Health Econ; 2010 Feb; 11(1):95-104. PubMed ID: 19967426
[TBL] [Abstract][Full Text] [Related]
36. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
Kobelt G
Value Health; 2014 Jul; 17(5):537-44. PubMed ID: 25128046
[TBL] [Abstract][Full Text] [Related]
37. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2004; 22(16):1071-95. PubMed ID: 15524495
[TBL] [Abstract][Full Text] [Related]
38. Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
Infante R; Lahita RG
Geriatrics; 2000 Mar; 55(3):30-2, 35-6, 39-40. PubMed ID: 10732003
[TBL] [Abstract][Full Text] [Related]
39. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis.
Merkesdal S; Ruof J; Mittendorf T; Zeidler H
Expert Opin Pharmacother; 2004 Sep; 5(9):1881-6. PubMed ID: 15330726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
